DK3102571T3 - Substituted pyrimidines useful as EGFR-T790M kinase inhibitors - Google Patents

Substituted pyrimidines useful as EGFR-T790M kinase inhibitors Download PDF

Info

Publication number
DK3102571T3
DK3102571T3 DK15746902.4T DK15746902T DK3102571T3 DK 3102571 T3 DK3102571 T3 DK 3102571T3 DK 15746902 T DK15746902 T DK 15746902T DK 3102571 T3 DK3102571 T3 DK 3102571T3
Authority
DK
Denmark
Prior art keywords
cancer
compound
disorder
pharmaceutical composition
mmol
Prior art date
Application number
DK15746902.4T
Other languages
Danish (da)
English (en)
Inventor
Dawei Zhang
Original Assignee
Jiangsu Medolution Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Medolution Ltd filed Critical Jiangsu Medolution Ltd
Application granted granted Critical
Publication of DK3102571T3 publication Critical patent/DK3102571T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15746902.4T 2014-02-04 2015-02-03 Substituted pyrimidines useful as EGFR-T790M kinase inhibitors DK3102571T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461965584P 2014-02-04 2014-02-04
PCT/CN2015/072179 WO2015117547A1 (en) 2014-02-04 2015-02-03 Substituted pyrimidines useful as egfr-t790m kinase inhibitors

Publications (1)

Publication Number Publication Date
DK3102571T3 true DK3102571T3 (en) 2018-05-07

Family

ID=53777338

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15746902.4T DK3102571T3 (en) 2014-02-04 2015-02-03 Substituted pyrimidines useful as EGFR-T790M kinase inhibitors

Country Status (8)

Country Link
US (1) US10167264B2 (cg-RX-API-DMAC7.html)
EP (1) EP3102571B1 (cg-RX-API-DMAC7.html)
JP (1) JP6257787B2 (cg-RX-API-DMAC7.html)
CN (1) CN105980377B (cg-RX-API-DMAC7.html)
DK (1) DK3102571T3 (cg-RX-API-DMAC7.html)
ES (1) ES2667847T3 (cg-RX-API-DMAC7.html)
NO (1) NO2718543T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015117547A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106554318A (zh) * 2015-09-25 2017-04-05 正大天晴药业集团股份有限公司 氘代二苯基氨基嘧啶化合物
CN106554347B (zh) * 2015-09-25 2020-10-30 浙江博生医药有限公司 Egfr激酶抑制剂及其制备方法和应用
CN105461640B (zh) * 2015-12-02 2017-11-21 芷威（上海）化学科技有限公司 一种酪氨酸激酶抑制剂的制备方法
CN106146406A (zh) * 2016-02-23 2016-11-23 深圳市塔吉瑞生物医药有限公司 一种取代的二氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN107344925B (zh) * 2016-05-04 2022-11-11 正大天晴药业集团股份有限公司 氘代二苯基氨基-三氟甲基嘧啶化合物
CN107088196A (zh) * 2017-02-27 2017-08-25 王涛 一种治疗骨质疏松症的药物组合物
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12365664B2 (en) 2019-06-20 2025-07-22 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of SRC tyrosine kinase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
NZ710636A (en) * 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
WO2013106792A1 (en) * 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
JP6317319B2 (ja) * 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の固体形態
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico

Also Published As

Publication number Publication date
JP6257787B2 (ja) 2018-01-10
JP2017505319A (ja) 2017-02-16
ES2667847T3 (es) 2018-05-14
EP3102571B1 (en) 2018-04-04
CN105980377A (zh) 2016-09-28
CN105980377B (zh) 2018-07-03
WO2015117547A1 (en) 2015-08-13
EP3102571A1 (en) 2016-12-14
US20170008856A1 (en) 2017-01-12
EP3102571A4 (en) 2016-12-14
US10167264B2 (en) 2019-01-01
NO2718543T3 (cg-RX-API-DMAC7.html) 2018-01-06

Similar Documents

Publication Publication Date Title
DK3102571T3 (en) Substituted pyrimidines useful as EGFR-T790M kinase inhibitors
CN105461695B (zh) 嘧啶或三嗪衍生物及其制备方法和用途
CN105408334B (zh) 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
KR20170031778A (ko) 피리딘 아미도피리미딘 유도체, 그의 제조 방법 및 용도
WO2013173254A1 (en) Bicyclic compounds as kinases inhibitors
JP2021512161A (ja) Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ−インダゾール誘導体およびその治療上の使用
CN105315285A (zh) 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
CA3188077A1 (en) Egfr inhibitor, preparation method therefor and application thereof
EP2847186A1 (en) Substituted aminoquinazolines useful as kinases inhibitors
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
AU2018337138B2 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
WO2016026423A1 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
US10159663B2 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
US9388160B2 (en) Quinazoline derivatives as kinases inhibitors and methods of use thereof
CN114763360A (zh) 手性大环化合物作为蛋白激酶抑制剂及其用途
KR20230163335A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
US11427559B2 (en) Substituted quinolines useful as kinase inhibitors
US10173995B2 (en) Pyridine compounds used as PI3 kinase inhibitors
CN120865102A (zh) Egfr和pd-1/pd-l1双靶点抑制剂、制备方法和用途
KR20150037207A (ko) Fms 키나아제 저해 활성을 갖는 피리미딘 화합물
HK40036028A (en) Inhibitors of mutant egfr family tyrosine-kinases
JP2006104195A (ja) ピリミジン誘導体及び医薬
KR20150001353A (ko) Fms 키나아제 저해 활성을 갖는 피리미딘 유도체